Biotechstockmarket.be informs you about important stock market related life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
- Innovative Diabetic Eye Disease Clinical and Pre-Clinical Portfolio Provides "Multiple Shots on Goal" - First Patients Enrolled in Phase II Clinical Study Evaluating THR-317 (anti-PlGF) for Diabetic Macular Edema (DME) - Cash Position - €80.1 Million at end of December 2016
ThromboGenics continues to advance its attractive portfolio of innovative medicines for the treatment of diabetic eye disease: 4 novel treatments for diabetic retinopathy (DR) - non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR), in the presence or absence of diabetic macular edema (DME)
Read the full results here.